The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever

Journal of Infection

Volumn 60, Issue 6, 2010, Pages 409-416

  Limper, M ^a,b   de Kruif, M D ^a   Duits, A J ^b   Brandjes, D P M ^a   van Gorp, E C M ^a,c  

^a Slotervaartziekenhuis ^*  (Netherlands)

^b Red Cross Blood Bank Foundation   (Netherlands Antilles)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune diseases; Biological markers; C reactive protein; Fever; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 6; PROCALCITONIN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT ONSET STILL DISEASE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BEHCET DISEASE; CROHN DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; KIDNEY CARCINOMA; LEUKEMIA; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; NONHODGKIN LYMPHOMA; PHEOCHROMOCYTOMA; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPORAL ARTERITIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ULCERATIVE COLITIS; VASCULITIS; VIRUS INFECTION;

BIOLOGICAL MARKERS; CALCITONIN; FEVER; HUMANS; INFECTION; PROTEIN PRECURSORS;

EID: 77953322360     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.016     Document Type: Review

References (70)

1. Nawar E.W., Niska R.W., Xu J. National hospital ambulatory medical care survey: 2005 emergency department summary. Adv Data 2007, 1-32.
2. Marnell L., Mold C., Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005, 117:104-111.
3. Meisner M. Biomarkers of sepsis: clinically useful?. Curr Opin Crit Care 2005, 11:473-480.
4. Pepys M.B., Hirschfield G.M. C-reactive protein and its role in the pathogenesis of myocardial infarction. Ital Heart J 2001, 2:804-806.
5. Becker K.L., Snider R., Nylen E.S. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008, 36:941-952.
6. Briel M., Schuetz P., Mueller B., Young J., Schild U., Nusbaumer C., et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008, 168:2000-2007.
7. Chirouze C., Schuhmacher H., Rabaud C., Gil H., Khayat N., Estavoyer J.M., et al. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002, 35:156-161.
8. Delevaux I., Andre M., Colombier M., Albuisson E., Meylheuc F., Begue R.J., et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?. Ann Rheum Dis 2003, 62:337-340.
9. Prat C., Sancho J.M., Dominguez J., Xicoy B., Gimenez M., Ferra C., et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008, 49:1752-1761.
10. Sakr Y., Sponholz C., Tuche F., Brunkhorst F., Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008, 36:396-407.
11. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006, 34:1996-2003.
12. van Rossum A.M., Wulkan R.W., Oudesluys-Murphy A.M. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 2004, 4:620-630.
13. Dandona P., Nix D., Wilson M.F., Aljada A., Love J., Assicot M., et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994, 79:1605-1608.
14. Meisner M., Schmidt J., Huttner H., Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 2000, 26(Suppl 2):S212-S216.
15. Assicot M., Gendrel D., Carsin H., Raymond J., Guilbaud J., Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
16. Lippi G., Schena F., Montagnana M., Salvagno G.L., Guidi G.C. Acute influence of aerobic physical exercise on procalcitonin. Eur J Clin Invest 2008, 38:784-785.
17. Quintana G., Medina Y.F., Rojas C., Fernandez A., Restrepo J.F., Rondon F., et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol 2008, 14:138-142.
18. Rose N.R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993, 14:426-430.
19. Bradley J.D., Brandt K.D., Katz B.P. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989, 32:45-53.
20. Olshaker J.S., Jerrard D.A. The erythrocyte sedimentation rate. J Emerg Med 1997, 15:869-874.
21. Smetana G.W., Shmerling R.H. Does this patient have temporal arteritis?. JAMA 2002, 287:92-101.
22. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
23. Schwenger V., Sis J., Breitbart A., Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 1998, 26:274-276.
24. Brunkhorst R., Eberhardt O.K., Haubitz M., Brunkhorst F.M. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intens Care Med 2000, 26(Suppl 2):S199-S201.
25. Gaitonde S., Samols D., Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008, 59:1814-1820.
26. Song M., Kellum J.A. Interleukin-6. Crit Care Med 2005, 33:S463-S465.
27. Malle E., De Beer F.C. Human serum amyloid A (SAA) protein: a prominent acute phase reactant for clinical practice. Eur J Clin Invest 1996, 26:427-435.
28. Obici L., Raimondi S., Lavatelli F., Bellotti V., Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009, 61:1435-1440.
29. Keersmaekers T., Claes K., Kuypers D.R., de Vlam K., Verschueren P., Westhovens R. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis 2009, 68:759-761.
30. Perry M.E., Stirling A., Hunter J.A. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol 2008, 27:923-925.
31. Adam B., Calikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behcet's disease. J Eur Acad Dermatol Venereol 2004, 18:318-320.
32. Scire C.A., Cavagna L., Perotti C., Bruschi E., Caporali R., Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006, 24:123-128.
33. Kuuliala A., Takala A., Siitonen S., Leirisalo-Repo M., Repo H. Cellular and humoral markers of systemic inflammation in acute reactive arthritis and early rheumatoid arthritis. Scand J Rheumatol 2004, 33:13-18.
34. Alavi A., Axford J.S. Glyco-biomarkers: potential determinants of cellular physiology and pathology. Dis Markers 2008, 25:193-205.
35. Yoo S.A., Kwok S.K., Kim W.U. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008, 2008:129873.
36. Samuels J., Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006, 18:108-117.
37. Hayem F. Is Still's disease an autoinflammatory syndrome?. Joint Bone Spine 2009, 76:7-9.
38. Fisher P.W., Ho L.T., Goldschmidt R., Semerdjian R.J., Rutecki G.W. Familial Mediterranean fever, inflammation and nephrotic syndrome: fibrillary glomerulopathy and the M680I missense mutation. BMC Nephrol 2003, 4:6.
39. Lachmann H.J., Hawkins P.N. Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther 2009, 11:212.
40. Korkmaz C., Ozdogan H., Kasapcopur O., Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002, 61:79-81.
41. Lachmann H.J., Sengul B., Yavuzsen T.U., Booth D.R., Booth S.E., Bybee A., et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006, 45:746-750.
42. Simon A., Bijzet J., Voorbij H.A., Mantovani A., van der Meer J.W., Drenth J.P. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J Intern Med 2004, 256:247-253.
43. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C reactive protein levels as markers of bacterial infection: a systematic review and meta analysis. Clin Infect Dis 2004, 39:206-217.
44. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 2008, 22:773-792.
45. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
46. Sartor R.B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995, 24:475-507.
47. van Deventer S.J. Tumour necrosis factor and Crohn's disease. Gut 1997, 40:443-448.
48. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
49. Maor I., Rainis T., Lanir A., Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci 2008, 53:2208-2214.
50. Huet O., Obata R., Aubron C., Spraul-Davit A., Charpentier J., Laplace C., et al. Plasma-induced endothelial oxidative stress is related to the severity of septic shock. Crit Care Med 2007, 35:821-826.
51. Huang H.H., Yan H.C., Han C.L., Yu F.C., Kao W.Y., Chen W.T. Association of in vitro oxidative stress, serum ferritin concentration and C-reactive protein in febrile emergency room patients. Clin Invest Med 2005, 28:48-54.
52. Marciano B.E., Rosenzweig S.D., Kleiner D.E., Anderson V.L., Darnell D.N., Anaya-O'Brien S., et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004, 114:462-468.
53. Herrlinger K.R., Dittmann R., Weitz G., Wehkamp J., Ludwig D., Schwab M., et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 2004, 10:229-233.
54. Bleeker-Rovers C.P., Vos F.J., de Kleijn E.M., Mudde A.H., Dofferhoff T.S., Richter C., et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 2007, 86:26-38.
55. Zell J.A., Chang J.C. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer 2005, 13:870-877.
56. Kallio R., Surcel H.M., Bloigu A., Syrjala H. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 2000, 36:889-894.
57. Kallio R., Bloigu A., Surcel H.M., Syrjala H. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 2001, 9:124-128.
58. Sudhoff T., Giagounidis A., Karthaus M. Serum and plasma parameters in clinical evaluation of neutropenic fever. Antibiot Chemother 2000, 50:10-19.
59. Oude Nijhuis C.S., Daenen S.M., Vellenga E., van der Graaf W.T., Gietema J.A., Groen H.J., et al. Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 2002, 44:163-174.
60. Ben Dor I., Haim M., Rechavia E., Murininkas D., Nahon M., Harell D., et al. Body temperature - a marker of infarct size in the era of early reperfusion. Cardiology 2005, 103:169-173.
61. Risoe C., Kirkeby O.J., Grottum P., Sederholm M., Kjekshus J.K. Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo. Br Heart J 1987, 57:28-31.
62. Guinea G.V., Atienza J.M., Fantidis P., Rojo F.J., Ortega A., Torres M., et al. Increases of corporal temperature as a risk factor of atherosclerotic plaque instability. Ann Biomed Eng 2008, 36:66-76.
63. Latini R., Bianchi M., Correale E., Dinarello C.A., Fantuzzi G., Fresco C., et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994, 23:1-6.
64. Georgilis K., Plomaritoglou A., Dafni U., Bassiakos Y., Vemmos K. Aetiology of fever in patients with acute stroke. J Intern Med 1999, 246:203-209.
65. Leira R., Rodriguez-Yanez M., Castellanos M., Blanco M., Nombela F., Sobrino T., et al. Hyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke. J Intern Med 2006, 260:343-349.
66. Stein P.D., Afzal A., Henry J.W., Villareal C.G. Fever in acute pulmonary embolism. Chest 2000, 117:39-42.
67. Kokturk N., Demir N., Oguzulgen I.K., Demirel K., Ekim N. Fever in pulmonary embolism. Blood Coagul Fibrinolysis 2005, 16:341-347.
68. Delevaux I., Andre M., Aumaitre O., Begue R.J., Colombier M., Piette J.C. Procalcitonin measurement for differential diagnosis between pulmonary embolism and pneumonia. Crit Care Med 2003, 31:661.
69. Takagi M., Egawa T., Motomura T., Sakuma-Mochizuki J., Nishimoto N., Kasayama S., et al. Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Clin Endocrinol (Oxf) 1997, 46:507-509.
70. Nieman L.K., Chanco Turner M.L. Addison's disease. Clin Dermatol 2006, 24:276-280.